MAM
CTMX icon

Meeder Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Meeder Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-92
Closed -$1K – 2496
2021
Q2 		$1K Sell
92
-5,423
-98% -$42.2K ﹤0.01% 2317
2021
Q1 		$43K Buy
+5,515
New +$43.7K ﹤0.01% 1156
2020
Q3 		– Sell
-3,158
Closed -$26K – 2201
2020
Q2 		$26K Sell
3,158
-4,783
-60% -$44.4K ﹤0.01% 1072
2020
Q1 		$60K Buy
7,941
+4,536
+133% +$31.6K ﹤0.01% 858
2019
Q4 		$28K Buy
+3,405
New +$23K ﹤0.01% 1236
2019
Q3 		– Sell
-1,431
Closed -$16K – 2157
2019
Q2 		$16K Buy
1,431
+1,028
+255% +$10.8K ﹤0.01% 1312
2019
Q1 		$4K Buy
+403
New +$5.96K ﹤0.01% 1430
2018
Q4 		– Sell
-1,764
Closed -$34K – 1724
2018
Q3 		$34K Sell
1,764
-669
-27% -$15.2K ﹤0.01% 891
2018
Q2 		$55.6K Buy
2,433
+911
+60% +$23.3K ﹤0.01% 734
2018
Q1 		$44K Buy
1,522
+779
+105% +$22.2K ﹤0.01% 700
2017
Q4 		$16K Buy
743
+32
+5% +$664 ﹤0.01% 990
2017
Q3 		$13K Buy
711
+433
+156% +$6.76K ﹤0.01% 1010
2017
Q2 		$4K Hold
278
– – ﹤0.01% 1241
2017
Q1 		$5K Sell
278
-263
-49% -$3.46K ﹤0.01% 1061
2016
Q4 		$6K Buy
+541
New +$6.55K ﹤0.01% 834

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Meeder Asset Management's CTMX Position: Q3 2021 in Review

Meeder Asset Management sold out of CytomX Therapeutics (CTMX) in Q3 2021, closing a stake of 92 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in CTMX in Q4 2016 and held it in 15 quarters. The position peaked at $60K in Q1 2020. 114 funds tracked by Wall St. Rank hold CTMX as of Q3 2021.

  • Meeder Asset Management reported no remaining CytomX Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Meeder Asset Management sold 92 CytomX Therapeutics shares in Q3 2021, an estimated $1K.
  • Meeder Asset Management first reported a position in CytomX Therapeutics in Q4 2016 and held it in 15 quarters.
  • Meeder Asset Management's CytomX Therapeutics position peaked at $60K in Q1 2020.
  • 114 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2021.

Based on Meeder Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.